The integration of anti-angiogenic drugs, PARP inhibitors, tyrosine kinase inhibitors, and particularly immune checkpoint inhibitors like pembrolizumab, has fundamentally improved outcomes for patients with recurrent or metastatic disease. This evidence concerns the gene PARP1 and metastatic neoplasm.